Schnitzler syndrome: An under-diagnosed clinical entity

Tania Jain, Chetan P. Offord, Robert A. Kyle, David M Dingli

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Schnitzler syndrome is considered to be a rare disorder characterized by a monoclonal IgM protein and chronic urticaria that is associated with considerable morbidity. We hypothesized that the syndrome may be under-recognized and patients may be deprived of highly effective therapy in the form of anakinra. We performed a retrospective search of the dysproteinemia database at Mayo Clinic as well as the medical records of all patients with chronic urticaria to determine the true incidence of the disease. We compared patients with the diagnosis of Schnitzler syndrome and those who met the criteria but in whom the syndrome was not recognized. Comparisons between groups were performed and survival curves determined. We identified 16 patients with diagnosed Schnitzler syndrome and an additional 46 patients who met diagnostic criteria. The monoclonal protein was IgMκ in 94% of patients. Therapy with anakinra in 4 patients led to rapid and complete resolution of symptoms. The median overall survival for this syndrome is over 12.8 years. Progression to lymphoma was only observed in 8% of patients; this is lower than previous reports. Schnitzler syndrome may be present in up to 1.5% of patients with a monoclonal IgM in their serum and likely under-recognized as a clinical syndrome.

Original languageEnglish (US)
Pages (from-to)1581-1585
Number of pages5
JournalHaematologica
Volume98
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Schnitzler Syndrome
Interleukin 1 Receptor Antagonist Protein
Immunoglobulin M
Urticaria
Survival
Medical Records
Lymphoma
Proteins

ASJC Scopus subject areas

  • Hematology

Cite this

Schnitzler syndrome : An under-diagnosed clinical entity. / Jain, Tania; Offord, Chetan P.; Kyle, Robert A.; Dingli, David M.

In: Haematologica, Vol. 98, No. 10, 01.10.2013, p. 1581-1585.

Research output: Contribution to journalArticle

Jain, Tania ; Offord, Chetan P. ; Kyle, Robert A. ; Dingli, David M. / Schnitzler syndrome : An under-diagnosed clinical entity. In: Haematologica. 2013 ; Vol. 98, No. 10. pp. 1581-1585.
@article{843391d8728e425aa03d7584298fc083,
title = "Schnitzler syndrome: An under-diagnosed clinical entity",
abstract = "Schnitzler syndrome is considered to be a rare disorder characterized by a monoclonal IgM protein and chronic urticaria that is associated with considerable morbidity. We hypothesized that the syndrome may be under-recognized and patients may be deprived of highly effective therapy in the form of anakinra. We performed a retrospective search of the dysproteinemia database at Mayo Clinic as well as the medical records of all patients with chronic urticaria to determine the true incidence of the disease. We compared patients with the diagnosis of Schnitzler syndrome and those who met the criteria but in whom the syndrome was not recognized. Comparisons between groups were performed and survival curves determined. We identified 16 patients with diagnosed Schnitzler syndrome and an additional 46 patients who met diagnostic criteria. The monoclonal protein was IgMκ in 94{\%} of patients. Therapy with anakinra in 4 patients led to rapid and complete resolution of symptoms. The median overall survival for this syndrome is over 12.8 years. Progression to lymphoma was only observed in 8{\%} of patients; this is lower than previous reports. Schnitzler syndrome may be present in up to 1.5{\%} of patients with a monoclonal IgM in their serum and likely under-recognized as a clinical syndrome.",
author = "Tania Jain and Offord, {Chetan P.} and Kyle, {Robert A.} and Dingli, {David M}",
year = "2013",
month = "10",
day = "1",
doi = "10.3324/haematol.2013.084830",
language = "English (US)",
volume = "98",
pages = "1581--1585",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

TY - JOUR

T1 - Schnitzler syndrome

T2 - An under-diagnosed clinical entity

AU - Jain, Tania

AU - Offord, Chetan P.

AU - Kyle, Robert A.

AU - Dingli, David M

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Schnitzler syndrome is considered to be a rare disorder characterized by a monoclonal IgM protein and chronic urticaria that is associated with considerable morbidity. We hypothesized that the syndrome may be under-recognized and patients may be deprived of highly effective therapy in the form of anakinra. We performed a retrospective search of the dysproteinemia database at Mayo Clinic as well as the medical records of all patients with chronic urticaria to determine the true incidence of the disease. We compared patients with the diagnosis of Schnitzler syndrome and those who met the criteria but in whom the syndrome was not recognized. Comparisons between groups were performed and survival curves determined. We identified 16 patients with diagnosed Schnitzler syndrome and an additional 46 patients who met diagnostic criteria. The monoclonal protein was IgMκ in 94% of patients. Therapy with anakinra in 4 patients led to rapid and complete resolution of symptoms. The median overall survival for this syndrome is over 12.8 years. Progression to lymphoma was only observed in 8% of patients; this is lower than previous reports. Schnitzler syndrome may be present in up to 1.5% of patients with a monoclonal IgM in their serum and likely under-recognized as a clinical syndrome.

AB - Schnitzler syndrome is considered to be a rare disorder characterized by a monoclonal IgM protein and chronic urticaria that is associated with considerable morbidity. We hypothesized that the syndrome may be under-recognized and patients may be deprived of highly effective therapy in the form of anakinra. We performed a retrospective search of the dysproteinemia database at Mayo Clinic as well as the medical records of all patients with chronic urticaria to determine the true incidence of the disease. We compared patients with the diagnosis of Schnitzler syndrome and those who met the criteria but in whom the syndrome was not recognized. Comparisons between groups were performed and survival curves determined. We identified 16 patients with diagnosed Schnitzler syndrome and an additional 46 patients who met diagnostic criteria. The monoclonal protein was IgMκ in 94% of patients. Therapy with anakinra in 4 patients led to rapid and complete resolution of symptoms. The median overall survival for this syndrome is over 12.8 years. Progression to lymphoma was only observed in 8% of patients; this is lower than previous reports. Schnitzler syndrome may be present in up to 1.5% of patients with a monoclonal IgM in their serum and likely under-recognized as a clinical syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84884919635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884919635&partnerID=8YFLogxK

U2 - 10.3324/haematol.2013.084830

DO - 10.3324/haematol.2013.084830

M3 - Article

C2 - 23812931

AN - SCOPUS:84884919635

VL - 98

SP - 1581

EP - 1585

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -